Business Context and Reporting Period
biote Corp. filed this Form 8-K on June 8, 2023, reporting the final results of its offer to exchange outstanding warrants and the related consent solicitation to amend the warrant agreement. The company’s Class A common stock trades under BTMD and its warrants under BTMDW on Nasdaq.
Material Transaction and Key Metrics
- Warrant holders were offered 0.23 shares of Class A common stock for each warrant validly tendered and not withdrawn.
- Approximately 8,191,336 Public Warrants, or 97.5% of outstanding Public Warrants, were tendered, including warrants submitted through guaranteed delivery.
- Approximately 4,464,900 Private Placement Warrants, or 87.4% of outstanding Private Placement Warrants, were tendered, including warrants submitted through guaranteed delivery.
- The company expected to accept and settle all validly tendered warrants on or before June 9, 2023.
- Consents approving the warrant amendment were received from approximately 97.5% of outstanding Public Warrants and 87.4% of outstanding Private Placement Warrants, exceeding the required 50% threshold.
- The company and Continental Stock Transfer & Trust Company entered into Amendment No. 1 to the Warrant Agreement on June 8, 2023.
- The amendment permits the company to require conversion of each remaining outstanding warrant into 0.207 shares of common stock, 10% below the 0.23-share exchange ratio offered in the tender offer.
- The company stated that it will exercise this right to exchange all remaining outstanding warrants for shares of common stock.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. It also does not quantify the total number of common shares expected to be issued in connection with the completed and planned warrant exchanges.
Guidance, Outlook, Risks, and Unusual Items
- The principal corporate action is the planned mandatory exchange of all remaining warrants, subject to the amendment’s notice and procedural requirements.
- Holders of remaining warrants must receive at least 15 days’ prior notice before the company’s fixed exchange date.
- The filing states that the offer and consent solicitation expired one minute after 11:59 p.m. Eastern Standard Time on June 7, but the text refers to “June 7, 2021,” which appears inconsistent with the 2023 filing and should be verified against the exhibits.
- The filing does not provide management guidance or a broader operating outlook.
Investor Verification Checklist
- Verify the final settlement date and the number of warrants actually accepted and exchanged.
- Confirm the number of remaining warrants subject to the mandatory exchange and the resulting potential common-stock dilution.
- Review Amendment No. 1 for the exact exchange mechanics, notice requirements, and treatment of different warrant classes.
- Investigate the apparent “June 7, 2021” date reference in the filing text.
- Review the accompanying press release for any additional transaction terms or management commentary.